Illumina, Broad Institute Partner On Secondary Genomic Analysis
Zacks Investment Research | Sep 30, 2019 11:56PM ET
Illumina Inc. (NASDAQ:ILMN) recently teamed up with the Broad Institute of MIT and Harvard to co-develop secondary genomic analysis algorithms and software. The partnership will combine Broad Institute’s open-source GATK algorithms with Illumina’s DRAGEN (Dynamic Read Analysis for GENomics) Bio-IT Platform to serve the purpose.
This partnership with the Broad is a major breakthrough on Illumina’s part to develop an advanced open-source software for commonly used methods including small variant (SNV) and large variant (CNV/SV) detection. In this context, last year, the company acquired Edico Genome and DRAGEN.
Financial terms of the deal were kept under wraps.
The GATK and DRAGEN at a Glance
The Broad Institute’s GATK identifies SNPs and indels in germline DNA and RNA sequencing data. In addition to variant callers, GATK includes utilities to perform related tasks, such as processing and quality control of high-throughput sequencing data.
Illumina, Inc. Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.